Screening and Management of the Hyperandrogenic Adolescent
- 1 October 2019
- journal article
- research article
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 134 (4) , e106-e114
Abstract
Although androgen excess can manifest in many ways, the most common and recognizable symptoms are hirsutism and acne. Reports of hirsutism and acne should be taken seriously because of their possible association with medical disorders, their substantial effect on self-esteem and quality of life, and the potential for psychosocial morbidity. In patients with symptoms of androgen excess, the differential diagnosis should include physiologic hyperandrogenism of puberty, idiopathic hyperandrogenism, and polycystic ovary syndrome (PCOS). There is a great deal of overlap between the symptoms of PCOS and those of normal puberty, which makes the diagnosis of PCOS in the adolescent difficult. Treatment of acne and hirsutism should not be withheld during the ongoing longitudinal evaluation for possible PCOS. On physical examination, body mass index, blood pressure, and signs of hyperandrogenism, such as acne and hirsutism, should be evaluated. Although guidelines differ on recommended laboratory studies, most include measurement of total testosterone, free testosterone, or both, and screening for nonclassic congenital adrenal hyperplasia with a 17-hydroxyprogesterone test. Elevation of the free or total testosterone level higher than the adult female normative values is a key diagnostic feature of biochemical hyperandrogenism. Because treatment is indicated only when symptoms are distressing to the patient, the degree to which acne or hirsutism bothers the patient should be assessed. Before initiation of any medical therapy, expectations of treatment should be discussed with the patient. Anticipatory guidance is critical to help patients understand the timeline for expected responses to therapy.Keywords
This publication has 27 references indexed in Scilit:
- Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome SocietyHuman Reproduction Update, 2011
- Polycystic ovarian morphology in postmenarchal adolescentsFertility and Sterility, 2011
- Polycystic ovary syndrome and cardiovascular risk in young patients treated with drospirenone-ethinylestradiol or contraceptive vaginal ring. A prospective, randomized, pilot studyFertility and Sterility, 2010
- Comprehensive clinical management of hirsutismGynecological Endocrinology, 2010
- Hormonal therapy for acne: why not as first line therapy? facts and controversiesClinics in Dermatology, 2010
- The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force reportFertility and Sterility, 2009
- Adolescent Female Acne: Etiology and ManagementJournal of Pediatric and Adolescent Gynecology, 2008
- Randomized, double‐blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hairInternational Journal of Dermatology, 2007
- Effect of oral versus transdermal steroidal contraceptives on androgenic markersAmerican Journal of Obstetrics and Gynecology, 2005
- Clinical and metabolic findings in adolescent females with hyperandrogenismJournal of Pediatric and Adolescent Gynecology, 2004